Literature DB >> 25715093

Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression.

Maureen Alivon1, Julie Giroux, Marie Briet, François Goldwasser, Stéphane Laurent, Pierre Boutouyrie.   

Abstract

BACKGROUND: Systemic hypertension is a frequent side effect of antiangiogenic drugs (AADs) and may represent a marker of efficacy on cancer. We hypothesized that large artery properties are affected by AADs, and contribute to the rise of blood pressure and may be better related to cancer progression and mortality than hypertension. METHODS AND
RESULTS: Participants were studied before AADs (V0), 10 days later (V1) and then every 2 weeks for 6 weeks (V1-V4). We included 57 consecutive patients in whom treatment with sorafenib (400 mg twice daily) or sunitinib (37.5-50 mg once daily) was indicated. The target dose could be adjusted according to tolerance and response. Aortic and carotid stiffness, brachial and central blood pressure and augmentation index were measured noninvasively at each visit. Data regarding cancer progression and mortality were collected at 6 months. Twenty-eight patients (49%) developed hypertension. Brachial SBP significantly increased during follow-up (V0-V1: +9.6 ± 15.2 mmHg, P < 0.001; V0-V4: +6.0 ± 17.8 mmHg, P = 0.04). Central BP, and aortic and carotid stiffness increased independently of brachial BP changes. Aortic and carotid stiffening were associated with cancer progression independently of BP changes [hazard risk 1.24 (1.01-1.51) and 1.34 (1.03-1.73), respectively; P < 0.05], but not with cancer mortality. Brachial SBP had no predictive value.
CONCLUSION: Large arteries stiffen during AAD treatment partly independently of BP changes. Arterial mechanical properties are associated with BP rise. Arterial stiffening is related with the effects of AAD on cancer progression independently of BP changes. Large artery properties might help monitor AAD therapy in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25715093     DOI: 10.1097/HJH.0000000000000550

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Failure properties and microstructure of healthy and aneurysmatic human thoracic aortas subjected to uniaxial extension with a focus on the media.

Authors:  Selda Sherifova; Gerhard Sommer; Christian Viertler; Peter Regitnig; Thomas Caranasos; Margaret Anne Smith; Boyce E Griffith; Ray W Ogden; Gerhard A Holzapfel
Journal:  Acta Biomater       Date:  2019-08-26       Impact factor: 8.947

2.  Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.

Authors:  Bart Spronck; Tammo Delhaas; Anouk Gw De Lepper; Julie Giroux; François Goldwasser; Pierre Boutouyrie; Maureen Alivon; Koen D Reesink
Journal:  Hypertens Res       Date:  2017-03-16       Impact factor: 3.872

3.  The hypertensive effect of sorafenib is abolished by sildenafil.

Authors:  Hubert Dabiré; Fatou Dramé; Nelly Cita; Bijan Ghaleh
Journal:  Cardiooncology       Date:  2020-07-13

4.  Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser.

Authors:  Erman Cilsal; Emine Alyamac Sukgen
Journal:  Cardiovasc J Afr       Date:  2020-01-13       Impact factor: 1.167

5.  Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.

Authors:  Kaisa M Mäki-Petäjä; Adam McGeoch; Lucy L Yang; Annette Hubsch; Carmel M McEniery; Paul A R Meyer; Fraz Mir; Parag Gajendragadkar; Nicola Ramenatte; Gayathri Anandappa; Sara Santos Franco; Simon J Bond; Carola-Bibiane Schönlieb; Yoeri Boink; Christoph Brune; Ian B Wilkinson; Duncan I Jodrell; Joseph Cheriyan
Journal:  Hypertension       Date:  2021-03-29       Impact factor: 10.190

Review 6.  Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.

Authors:  Audrey Bellesoeur; Edith Carton; Jerome Alexandre; Francois Goldwasser; Olivier Huillard
Journal:  Drug Des Devel Ther       Date:  2017-09-21       Impact factor: 4.162

7.  Anticancer Therapy-Related Increases in Arterial Stiffness: A Systematic Review and Meta-Analysis.

Authors:  Shannon K Parr; Jia Liang; Keri L Schadler; Susan C Gilchrist; Catherine C Steele; Carl J Ade
Journal:  J Am Heart Assoc       Date:  2020-07-10       Impact factor: 5.501

Review 8.  Hypertension in cancer patients treated with anti-angiogenic based regimens.

Authors:  Yishay Wasserstrum; Ran Kornowski; Pia Raanani; Avi Leader; Oren Pasvolsky; Zaza Iakobishvili
Journal:  Cardiooncology       Date:  2015-12-07

Review 9.  Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities.

Authors:  Maher Chaar; Jeff Kamta; Sihem Ait-Oudhia
Journal:  Onco Targets Ther       Date:  2018-09-25       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.